Welcome to our dedicated page for Forian news (Ticker: FORA), a resource for investors and traders seeking the latest updates and insights on Forian stock.
Forian Inc. (Nasdaq: FORA) is a data processing and analytics company focused on the life sciences, healthcare and financial services industries. This news page aggregates company-issued announcements, financial updates and other disclosures so readers can follow how Forian’s data science driven information and analytics solutions evolve over time.
In its public communications, Forian highlights developments related to its healthcare information platform, clinical data lake and proprietary information products. News items include quarterly and annual financial results, where the company reports revenue, income or loss from continuing operations, Adjusted EBITDA and other financial measures, as well as commentary on its strategic priorities. These releases also describe changes in data sources, expansion of assets such as the Chronos™ data lake and the company’s efforts to differentiate its offerings for life sciences and healthcare customers.
Corporate and strategic announcements form another key category of Forian news. The company has announced the divestiture of BioTrack to focus on core healthcare and life sciences activities, the acquisition of Kyber Data Science to add advanced healthcare data analytics and machine learning capabilities for financial services clients, and a partnership with Databricks to make its Chartis™ product available through the Databricks Marketplace. Updates on governance and capital markets matters, including conference participation, changes in directors, accounting firm transitions and proposals related to redomiciliation and potential take-private transactions, are also disclosed through press releases and SEC-related communications.
Investors, analysts and industry participants can use this news feed to review Forian’s most recent earnings announcements, strategic transactions, product-related updates and governance developments. Regularly reviewing these items can provide context on how the company manages its large-scale healthcare data assets, expands its analytics capabilities and addresses both healthcare and financial services customer needs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Forian Inc. (Nasdaq: FORA) reported a 37% year-over-year revenue growth in Q4 2022, totaling $7.9 million, with healthcare information revenue increasing 64%. The company reduced its net loss to $3.6 million or $0.11 per share, down from $8.0 million in Q4 2021. For the full year, total revenue reached $28.0 million, a 66% increase from 2021. Forian divested BioTrack for $30 million in February 2023, enhancing its balance sheet. The company expects 25% to 37% revenue growth in healthcare information in 2023, aiming for positive adjusted EBITDA in the second half of the year.
Forian Inc. (Nasdaq: FORA) announced it will release its fourth quarter and full year 2022 financial results on March 27, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. (ET) the same day. Investors can register for the call and access the webcast live on the company’s website. Forian provides data science-driven information and analytics solutions to healthcare and life sciences sectors, focusing on optimizing operational and financial performance for its clients. Forward-looking statements highlight potential risks and uncertainties that may affect future performance, suggesting caution in reliance on these projections.